Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildrakizumab in Moderate to Severe Genital Psoriasis
NCT06611163Phase 3Active, not recruiting
- Sponsor
- Sun Pharma
- Start
- Mar 2025
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in genital psoriasis comparing Tildrakizumab 100 mg with Placebo (2 arms). Primary endpoint: Modified Static Physician's Global Assessment of Genitalia Response at 16 weeks. Started Mar 2025; status: active, not recruiting.
02
Drugs
tildrakizumab
03
Conditions
genital psoriasis
Beyond the preview
Go deeper on NCT06611163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06611163.